Colonic ulcers accompanying collagenous colitis: implication of nonsteroidal anti-inflammatory drugs

Kakar, Sanjay; Pardi, Darrell S.; Burgart, Lawrence J.
August 2003
American Journal of Gastroenterology;Aug2003, Vol. 98 Issue 8, p1834
Academic Journal
: ObjectivesA small minority of otherwise typical collagenous colitis (CC) patients also have mucosal ulceration (CC-U). We studied the association of CC-U cases with ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) as a possible explanation for the mucosal ulceration.: MethodsClinical information and histological features were reviewed in nine cases of biopsy-diagnosed CC-U. Biopsies from 18 unselected cases of CC without ulceration were reviewed for comparison.: ResultsOf nine patients with CC-U, seven (77.8%) had a history of NSAID ingestion, compared with four of 18 CC controls (20.2%) (p = 0.006). The diarrhea resolved after cessation of NSAID use in four CC-U patients, partially resolved in one patient, and persisted in one patient. The outcome was not available in one patient. Of the two CC-U patients who did not use NSAIDs, one patient was taking lisinopril (angiotensin-converting enzyme inhibitor), and the diarrhea resolved after stopping the drug; the ulceration in the second patient was thought to be ischemic in origin.: ConclusionCollagenous colitis with ulceration has a strong association with NSAID ingestion. Evaluation of medications and cessation of NSAIDs should be considered as a therapeutic option in cases of collagenous colitis with colonic ulceration.


Related Articles

  • Continuing Education Case Study Quiz.  // Hospital Pharmacy;Jun2007, Vol. 42 Issue 6, p551 

    A quiz about the use of mesalamine multimatrix (MMx) tablet among patients with ulcerative colitis is presented.

  • Oral and rectal mesalamine for ulcerative colitis. Miller, Karl // American Family Physician;6/1/1998, Vol. 57 Issue 11, p2858 

    Examines the medicinal properties of the anti-inflammatory agents in connection with the primary therapy for ulcerative colitis. Enrolling of sixty patients with mild or moderate distal ulcerative colitis; Completion of the disease activity index.

  • Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Pruitt, Ronald; Hanson, John; Safdi, Michael; Wruble, Lawrence; Hardi, Robert; Johanson, John; Koval, George; Riff, Dennis; Winston, Barry; Cross, Amanda; Doty, Pamela; Johnson, Lorin K. // American Journal of Gastroenterology;Dec2002, Vol. 97 Issue 12, p3078 

    OBJECTIVE:Balsalazide is a novel azo-bonded 5-aminosalicylic acid treatment for mild-to-moderate ulcerative colitis. The study objective was to compare symptomatic remission rates with balsalazide and mesalamine while controlling for extent of disease and time since diagnosis in patients with...

  • New UC drug formulation.  // Gastrointestinal Nursing;Oct2011, Vol. 9 Issue 8, p9 

    The article reports the launch of Pentasa (mesalamine) 1g tablet for the treatment of mild-to-moderate ulcerative colitis by Ferring Pharmaceuticals.

  • Controlled trial of azathioprine in chronic ulcerative colitis. Kirk, A.P.; Lennard-Jones, J.E. // British Medical Journal (Clinical Research Edition);5/1/1982, Vol. 284 Issue 6325, p1291 

    Evaluates the controlled trial of azathioprine in chronic ulcerative colitis. Infusion of prednisolone on patients; Complication in placebo colectomy; Therapeutic use of azathioprine.

  • Research brief: NSAIDs trigger bowel disease relapses.  // GP: General Practitioner;3/3/2006, p9 

    The article reports that non-selective nonsteroidal anti-inflammatory agents may cause relapses in patients with ulcerative colitis or Crohn's disease, according to a study from Great Britain.

  • Fecal Calprotectin Evaluation in Patients with Ulcerative Colitis. Dogan, Tolga; Agilli, Mehmet // Digestive Diseases & Sciences;Apr2015, Vol. 60 Issue 4, p1109 

    No abstract available.

  • COLAZAL "FOOD EFFECT" APPLICATION GRANTED FDA APPROVAL.  // Biotech Business;Nov2006, Vol. 19 Issue 11, p8 

    The article reports on the approved labeling for colazal from Salix Pharmaceuticals, Ltd. in North Carolina. Labeling for colazal, an anti-inflammatory drug for active ulcerative colitis, was approved by the U.S. Food and Drug Administration. The nature of Salix Pharmaceuticals and implications...

  • New indication for ulcerative colitis.  // Geriatrics;Nov97, Vol. 52 Issue 11, p24 

    Reports the approval of the US Food and Drug Administration on mesalamine for the treatment of mildly-to-moderately active ulcerative colitis. Recommended dosage of mesalamine; Its adverse reaction.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics